Diabetic nephropathy (DN) is a major cause of CKD that accounts for 30%–47% cases, some new drugs such as DPP-4 Inhibitors (sitagliptin, vildagliptin, saxagliptin, alogliptin and linagliptin, and preclinical), GLP-1 analogues (exenatide, liraglutide), sodium glucose cotransporter-2 (SGLT2) inhibitor (dapagliflozin, canagliflozin and empagliflozin) and so on show renal protection in DN (Schernthaner et al., 2014; Sharma et al., 2017; Sharma et al., 2018a; Kelly et al., 2019). This evidence concerns the gene DPP4 and liver dysplastic nodule.